01:43 PM EDT, 03/20/2026 (MT Newswires) -- Rhythm Pharmaceuticals ( RYTM ) has selected PANTHERx Rare as the exclusive US pharmacy distribution partner for the expanded indication of Imcivree, or setmelanotide, to treat acquired hypothalamic obesity in patients aged 4 years and older, PANTHERx Rare said Friday.

Acquired hypothalamic obesity is a rare disease with weight gain caused by an injury to the hypothalamus, according to a statement.

The financial terms of the arrangement were not disclosed.

Price: 89.18, Change: -1.14, Percent Change: -1.26